Galapagos' JAK1 inhibitor filgotinib (GLPG0634) meets primary and other key efficacy endpoints after 12 weeks of treatment in DARWIN 1 Phase 2B study
(Thomson Reuters ONE) -
* ACR20 scores up to 80% at 12 weeks
* Statistically significant ACR50 and DAS28(CRP) scores with all doses
* Patient-reported improvements observed after one week of treatment
* Safety profile is consistent with previous filgotinib RA studies
Webcast presentation of the results to be held on 15 April 2015, 16.00 CET/10 AM
EDT/7 AM PDT, +32 2 789 2126, access code 5188327, more call number info further
down
Mechelen, Belgium; 14 April 2015: Galapagos NV (Euronext: GLPG) announced today
that the selective JAK1 inhibitor filgotinib showed improvements in signs and
symptoms of active rheumatoid arthritis and met key efficacy endpoints after 12
weeks of treatment with filgotinib as an add-on to methotrexate, or MTX, in the
DARWIN 1 Phase 2B study. The study achieved its primary endpoint with a
statistically significant improvement in ACR20 score versus placebo after 12
weeks of treatment at a daily dose of 200 mg. Statistically significant ACR50
scores were achieved with all dose levels and dose regimens. Statistically
significant improvement in DAS28(CRP) was seen within one week. In this study,
filgotinib was well tolerated. Hemoglobin levels increased. The total
cholesterol over HDL ratio improved with dose. These first results in the
ongoing 24 week study are consistent with the efficacy/safety profile of
filgotinib observed in the prior 4-week clinical studies.
DARWIN 1 is an ongoing, 24 week, double-blind, placebo-controlled evaluation of
filgotinib, as once- and twice-daily administration (QD and BID dosing) at 3
daily dose levels. Results were reported for 594 patients with moderate to
severe rheumatoid arthritis who showed an inadequate response to methotrexate
and who remained on their background therapy of methotrexate. These patients
received filgotinib or placebo and were evaluated up to 12 weeks, the time of
the primary endpoint of the study. Galapagos expects to report the full 24 week
results for DARWIN 1 around the middle of the year.
Summary of the ACR/DAS28(CRP) scores at 12 weeks treatment:
+---------------------+----------------------+
| Once-daily dosing | Twice-daily dosing |
+-------------------------+-------+-----+-------+-------+------+-------+-------+
| |Placebo|50 mg|100 mg |200 mg |25 mg | 50 mg |100 mg |
| | n=86 |n=82 | n=85 | n=86 | n=86 | n=85 | n=84 |
+-------------------------+-------+-----+-------+-------+------+-------+-------+
|ACR20 responders, NRI, % | 45 | 56 | 62 | 69* | 57 | 59 | 80*** |
+-------------------------+-------+-----+-------+-------+------+-------+-------+
|ACR50 responders, NRI, % | 15 | 32* | 39** | 43*** | 28* | 34* | 55*** |
+-------------------------+-------+-----+-------+-------+------+-------+-------+
|ACR70 responders, NRI, % | 8 | 16 | 20 | 24* | 14 | 19 | 31** |
+-------------------------+-------+-----+-------+-------+------+-------+-------+
|DAS28(CRP), mean change | -1.2 |-1.8*|-2.2***|-2.5***|-1.9**|-2.1***|-2.8***|
|from baseline, LOCF § | | | | | | | |
+-------------------------+-------+-----+-------+-------+------+-------+-------+
* p< 0.05 vs. placebo; ** p<0.01 vs. placebo; *** p<0.001 vs. placebo; ACR
scores based on intent to treat (ITT) analysis, with non-responder imputation
(NRI).
§ Mean baseline DAS28(CRP) varied between 6.0 and 6.2. The DAS28(CRP) is
analyzed on a last observation carried forward (LOCF) basis.
Overall, there were no statistically relevant differences for the once-daily and
twice-daily dosing regimens. The results suggest a rapid onset of activity,
already after one week of treatment.
Over all dose groups including placebo, 1.7% of patients stopped treatment
during the study for safety reasons. Because of the low number of
discontinuations, the actual distribution across treatment groups is not
disclosed to prevent individual treatment unblinding while the study is still
ongoing. Serious (1.3% overall) and non-serious treatment-emergent adverse
events were evenly spread over the dose groups including placebo. The rare
frequency adverse events remain blinded for the treatment group and include 3
cases (0.5% of patients) of serious infections. Consistent with its selective
JAK1 inhibition, filgotinib treatment led to a dose-dependent improvement in
hemoglobin (up to 0.4 g/dL, or 3.7% increase from baseline). All lipid
fractions including HDL and LDL increased, with the largest percentage increase
in HDL leading to an improved total cholesterol over HDL ratio (atherogenic
index) at 200 mg/day.
"The last decade saw an important progress in RA treatment with biologicals,"
said Prof. René Westhovens from the University of Leuven, Belgium, and Principal
Investigator for DARWIN 1. "The current data with this oral drug spell hope for
a potential future treatment option that combines fast onset of action and ease
of administration. I am particularly impressed by the rapid improvement
reported by the patients. Also the increase in hemoglobin is important for my
patients, as this may lessen fatigue and enhance their overall well-being."
"I am very pleased to see that filgotinib treatment in DARWIN 1, one of the
largest Phase 2 studies in RA to date, shows consistent efficacy with fast onset
of action. Its selective inhibition of JAK1 also leads to a differentiated
safety profile, as measured by an improvement in hemoglobin and overall lipid
profile. Today's results with 12 weeks' treatment with filgotinib met the key
efficacy endpoints and are in line with what Galapagos showed in two previous 4-
week studies in RA patients. Based on these 12-week results in RA, we believe
that filgotinib has a promising future to address a significant medical need.
We look forward to seeing the DARWIN 2 monotherapy results in just a few weeks,"
said Dr Piet Wigerinck, Chief Scientific Officer of Galapagos.
About the DARWIN 1 trial and its measures
The primary endpoint of the DARWIN 1 study is efficacy in terms of percentage of
subjects achieving an ACR20 response after 12 weeks of treatment. In accordance
with the protocol for the DARWIN 1 study, at week 12, subjects on placebo or
lower doses of filgotinib who have not achieved 20% improvement in swollen joint
count and tender joint count will be re-randomized automatically to another
treatment arm with either a 50 mg (twice daily) or 100mg (once daily) dose.
Subjects in the other groups will maintain their randomized treatment until
week 24. Secondary trial objectives include efficacy in terms of the percentage
of subjects achieving an ACR20 response at week 24, ACR50 and ACR70 response and
other disease activity measures, as well as safety and tolerability and effects
on fatigue and quality of life.
The improvement of rheumatoid arthritis can be assessed using composite scores
as recommended by the American College of Rheumatology, or ACR. The ACR
criteria measure improvement in tender and swollen joint counts and include
other parameters which take into account the patient's and physician's
assessment of disease, pain, and an anti-inflammatory biomarker. These clinical
and laboratory disease activity parameters are combined to form a composite
score and are expressed as percentages of clinical response that are known as
ACR20, ACR50, and ACR70. An ACR20 score represents at least a 20% improvement in
these criteria and is considered a modest improvement in a patient's disease. An
ACR50 and ACR70 represent a minimal 50% and 70% improvement in the response
criteria, respectively, and each is considered evidence of a substantial
improvement in a patient's disease.
The DAS28(CRP), or the Disease Activity Score, considers 28 tender and swollen
joint counts, general health, plus levels of an inflammatory biomarker.
DAS28(CRP) is used to give an overall picture of the disease state, resulting in
a score on a scale from 0 to 10 indicating current RA disease activity, whereby
remission is less than or equal to 2.6, low disease activity is less than or
equal to 3.2, moderate disease activity is less than or equal to 5.1, and high
disease activity is >5.1.
Conference call and webcast presentation
Galapagos will conduct a conference call open to the public tomorrow, 15 April
2015, at 16:00 CET/10 AM EDT/7 AM PDT, which will also be webcast. To
participate in the conference call, please call one of the following numbers ten
minutes prior to commencement:
Confirmation Code: 5188327
London, United Kingdom: +44 20 3427 1903
Toll free - United Kingdom: 0800 279 4977
New York, United States of America: +1646 254 3366
Toll free - United States of America: 1877 280 1254
Amsterdam, Netherlands: +31 20 716 8256
Toll free - Netherlands: 0800 020 2577
Brussels, Belgium: +32 2 789 2126
Toll free - Belgium: 0800 58032
Paris, France: +33 1 76 77 22 24
Toll free - France: 0805 631 579
A question and answer session will follow the presentation of the results. Go
to www.glpg.com to access the live audio webcast. The archived webcast, PDF of
the slides, and a transcript will also be available on the Galapagos website
later in the day.
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is a clinical-stage biotechnology company
specialized in the discovery and development of small molecule medicines with
novel modes of action, with a pipeline comprising three Phase 2 programs, two
Phase 1 trials, five pre-clinical studies, and 20 discovery small-molecule and
antibody programs in cystic fibrosis, inflammation, and other indications. In
the field of inflammation, AbbVie and Galapagos signed a collaboration agreement
for the development and commercialization of filgotinib. Filgotinib is an
orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid
arthritis and potentially other inflammatory diseases, currently in Phase 2B
studies in RA and in Phase 2 in Crohn's disease. AbbVie and Galapagos also
signed a collaboration agreement in cystic fibrosis to develop and commercialize
molecules that address mutations in the CFTR gene. Potentiator GLPG1837 is
currently in a Phase 1 trial, and corrector GLPG2222 is at the pre-clinical
candidate stage. GLPG1205, a first-in-class inhibitor of GPR84 and fully-owned
by Galapagos, is currently being tested in a Phase 2 proof-of-concept trial in
ulcerative colitis patients. GLPG1690, a fully proprietary, first-in-class
inhibitor of autotaxin, has shown favorable safety in a Phase 1 trial and is
expected to enter Phase 2 in idiopathic pulmonary fibrosis. The Galapagos
Group, including fee-for-service subsidiary Fidelta, has approximately 400
employees, operating from its Mechelen, Belgium headquarters and facilities in
The Netherlands, France, and Croatia. Further information at: www.glpg.com
CONTACT
Galapagos NV
Elizabeth Goodwin, Head of Corporate Communications & IR
Tel: +31 6 2291 6240
ir(at)glpg.com
Galapagos forward-looking statements
This release may contain forward-looking statements, including, without
limitation, statements concerning anticipated progress, objectives and
expectations regarding the commercial potential of our product candidates,
intended product development, clinical activity timing, and other objectives and
explanations, all of which involve certain risks and uncertainties. These
statements are often, but are not always, made through the use of words or
phrases such as "believes," "anticipates," "expects," "intends," "plans,"
"seeks," "estimates," "may," "will," "could," "stands to," "continues," "we
believe," "we intend," as well as similar expressions. Such forward-looking
statements may involve known and unknown risks, uncertainties and other factors
which might cause the actual results, financial condition, performance or
achievements of Galapagos, or industry results, to be materially different from
any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Among the
factors that may result in differences are the inherent uncertainties associated
with competitive developments, clinical trial and product development
activities, regulatory approval requirements and estimating the commercial
potential of our product candidates. Given these uncertainties, the reader is
advised not to place any undue reliance on such forward-looking statements.
These forward-looking statements speak only as of the date of publication of
this document. Galapagos expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change in its
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based, unless required by law or
regulation.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via GlobeNewswire
[HUG#1911231]
Unternehmensinformation / Kurzprofil:
Datum: 14.04.2015 - 22:01 Uhr
Sprache: Deutsch
News-ID 385770
Anzahl Zeichen: 15399
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 158 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Galapagos' JAK1 inhibitor filgotinib (GLPG0634) meets primary and other key efficacy endpoints after 12 weeks of treatment in DARWIN 1 Phase 2B study"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
